Eli Lilly and BioArctic AB Announce Strategic Research and Collaboration Agreement

STOCKHOLM and INDIANAPOLIS — American pharmaceutical giant Eli Lilly and Company (NYSE: LLY) and Swedish biotechnology firm BioArctic AB (Nasdaq Stockholm: BBIOB) have officially entered into a strategic research and collaboration agreement. The partnership aims to leverage BioArctic’s proprietary drug discovery technologies and Lilly’s extensive clinical development capabilities to identify and develop novel therapeutic candidates. The alliance signals a major step forward in addressing complex neurodegenerative disorders, an area where both companies have recently secured landmark clinical and regulatory achievements.

Stockholm-based BioArctic is widely recognized for its pioneering work in developing selective antibody therapies targeting misfolded proteins. Notably, the company’s previous research collaboration with Eisai led to the development of lecanemab (marketed as Leqembi), a breakthrough disease-modifying treatment for early Alzheimer’s disease. Eli Lilly has similarly solidified its position as a powerhouse in the neuroscience space, recently launching its own Alzheimer’s therapy, Kisunla (donanemab). By joining forces, the two companies aim to harness BioArctic’s advanced research platforms—including potentially their proprietary BrainTransporter™ technology, which enhances the passage of immunotherapies across the blood-brain barrier—to target next-generation pathological targets in the central nervous system.

Key Highlights of the Agreement:

• Focus Areas: Early-stage research targeting neurodegenerative disease pathologies and specialized drug delivery mechanisms.
• Development Rights: Eli Lilly retains the option to acquire exclusive global licensing and commercialization rights for successfully developed candidates.
• Strategic Alignment: Combines BioArctic’s cutting-edge biotechnology platform with Lilly’s massive global clinical trial infrastructure and commercial scale.

Under the terms of the agreement, the collaboration will initially focus on early-stage research, with Lilly providing funding and research support. If successful, the deal is expected to yield substantial milestone-based payments and future royalties for BioArctic, while granting Lilly a robust pipeline of high-potential assets to sustain its long-term growth in the highly competitive neurology sector. Industry experts view the deal as a mutually beneficial alignment of strengths. For Lilly, the partnership secures a pipeline of innovative candidates to defend its market-leading position, while for BioArctic, aligning with a well-capitalized global partner validates its underlying science and provides the financial resources required to scale its proprietary research.